quinazolines has been researched along with Orphan Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baudin, E; Chougnet, CN; Leboulleux, S; Schlumberger, M | 1 |
| Chen, Z; Wu, JH; Zhang, X; Zhao, J | 1 |
| Choi, YS; Kong, SH; Seong, JY; Suh, HS | 1 |
| Goozner, M | 1 |
1 review(s) available for quinazolines and Orphan Diseases
| Article | Year |
|---|---|
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Humans; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Rare Diseases; Thyroid Neoplasms | 2014 |
3 other study(ies) available for quinazolines and Orphan Diseases
| Article | Year |
|---|---|
Case Report: Bazex Syndrome Associated With Pulmonary Adenocarcinoma.
Topics: Acitretin; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms; Carcinoma, Basal Cell; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Gefitinib; Humans; Hypotrichosis; Immunohistochemistry; Lung Neoplasms; Lymph Nodes; Male; Paraneoplastic Syndromes; Quinazolines; Radiography; Rare Diseases; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2016 |
Necrolytic Migratory Erythema-like Skin Lesion During Gefitinib Treatment: A Rare Cutaneous Adverse Reaction.
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Necrolytic Migratory Erythema; Protein Kinase Inhibitors; Quinazolines; Rare Diseases; Risk Assessment; Withholding Treatment | 2016 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |